Document Detail

Prasugrel (Effient) vs. clopidogrel (Plavix).
MedLine Citation:
PMID:  19738549     Owner:  NLM     Status:  MEDLINE    
The FDA has approved prasugrel (Effient--Lilly/Daiichi Sankyo), an oral antiplatelet drug, for use with aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS) being managed with percutaneous coronary intervention (PCI).1 It will compete with clopidogrel (Plavix) for such use.
Related Documents :
11231699 - New approaches to diagnosis and management of unstable angina and non-st-segment elevat...
8578489 - Clinical trials of primary and secondary prevention of thrombosis and restenosis.
17696569 - Incremental effect of clopidogrel on important outcomes in patients with cardiovascular...
19778669 - Cost effectiveness of enoxaparin in acute st-segment elevation myocardial infarction: t...
17174639 - Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled t...
11145489 - Novel dosing regimen of eptifibatide in planned coronary stent implantation (esprit): a...
2264479 - Cardiac myxoma as the cause of death in an infant.
18457349 - Cine-mri versus two-dimensional echocardiography to measure in vivo left ventricular fu...
1786519 - Regional coronary haemodynamic effects of two inhibitors of nitric oxide synthesis in a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Medical letter on drugs and therapeutics     Volume:  51     ISSN:  1523-2859     ISO Abbreviation:  -     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-09     Completed Date:  2009-09-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985240R     Medline TA:  Med Lett Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  69-70     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Approval / methods
Piperazines / adverse effects,  economics,  pharmacology,  therapeutic use*
Platelet Aggregation Inhibitors / adverse effects,  economics,  pharmacology,  therapeutic use*
Randomized Controlled Trials as Topic / methods
Thiophenes / adverse effects,  economics,  pharmacology,  therapeutic use*
Ticlopidine / adverse effects,  analogs & derivatives*,  economics,  pharmacology,  therapeutic use
United States
Reg. No./Substance:
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Thiophenes; 0/prasugrel; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Primary care in the ED - Why?
Next Document:  Calcitriol (Vectical) for mild to moderate plaque psoriasis.